Form 4: Cocrystal Pharma Director Fred Hassan Reports Acquisition of Restricted Stock Units

Director Fred Hassan reports acquisition of 8,067 restricted stock units (RSUs) in Cocrystal Pharma, Inc.

Summary

• On October 9, 2024, Fred Hassan, a director of Cocrystal Pharma, Inc., acquired 8,067 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of Cocrystal Pharma's common stock each.
• One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.
• Following the transaction, Hassan beneficially owns 1,023,296 shares of Cocrystal Pharma's common stock.
• The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard reporting of stock unit acquisition. The acquisition itself can be seen as a positive sign, but the document is purely informational.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future.

Future Outlook

The remaining RSUs will vest in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. The RSUs will vest in full upon a Change of Control as defined in the 2015 Equity Incentive Plan.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates